Overview

Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis

Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of combination therapy with etanercept and narrow-band (NB) UVB phototherapy for the treatment of psoriasis in a pilot study. This is a Phase 4 clinical study being conducted under an Amgen Investigational New Drug Application (IND).
Phase:
Phase 4
Details
Lead Sponsor:
Amgen
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Etanercept